Abstract
A biosimilar is a drug that is highly similar to a biologic drug and has been shown to have no clinically meaningful difference from its originator drug despite minor differences in clinically inactive components. In light of the increasing rates of diabetes and costs to the Canadian healthcare system, the use of biosimilar insulins is intended to increase the affordability of biologics. This article will review the available biosimilars approved in Canada, safety and efficacy studies, and the advantages and potential concerns regarding the switch to biosimilar insulins.
Reference20 articles.
1. Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014 Oct;127(10 Suppl):S25-38.
2. Fact Sheet: Biosimilar Biologic Drugs. Health Canada. http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/fs-fi/fs-fi_seb-pbu_07-2006-eng.php.
3. Diabetes, Biologic Drugs, and Biosimilar Insulins: A Position Statement. Diabetes Canada, 2020.
4. Keon, J. “Op-ed: The case for an Ontario biosimilar switching policy.” Biosimilars Canada, November 2021. https://biosimilarscanada.ca/news/news-releases.
5. Joshi SR, et al. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective. Expert Opin Biol Th. 2022:1-12.